IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v31y2013i8p703-718.html
   My bibliography  Save this article

Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence

Author

Listed:
  • Chantal Gils
  • Saskia Groot
  • William Redekop
  • Miriam Koopman
  • Cornelis Punt
  • Carin Uyl-de Groot

Abstract

The ICERs of the different scenarios that resulted from combining MOSAIC trial data with data from Dutch daily practice all suggest that FL + oxaliplatin is cost-effective versus FL alone in the adjuvant treatment of colon cancer. This article illustrates how one could design and implement a real-world cost-effectiveness study to yield internally valid results that could also be generalisable. Copyright Springer International Publishing Switzerland 2013

Suggested Citation

  • Chantal Gils & Saskia Groot & William Redekop & Miriam Koopman & Cornelis Punt & Carin Uyl-de Groot, 2013. "Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence," PharmacoEconomics, Springer, vol. 31(8), pages 703-718, August.
    • Handle: RePEc:spr:pharme:v:31:y:2013:i:8:p:703-718
    DOI: 10.1007/s40273-013-0061-6
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-013-0061-6
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-013-0061-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. M. Campioni & I. Agirrezabal & R. Hajek & J. Minarik & L. Pour & I. Spicka & S. Gonzalez-McQuire & P. Jandova & V. Maisnar, 2020. "Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(2), pages 219-233, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:31:y:2013:i:8:p:703-718. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.